Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis
- PMID: 18787216
- PMCID: PMC2588492
- DOI: 10.1164/rccm.200806-892OC
Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis
Abstract
Rationale: Linezolid, the first oxazolidinone approved for clinical use, has effective in vitro and promising in vivo activity against Mycobacterium tuberculosis.
Objectives: To evaluate the early and extended early bactericidal activity of linezolid in patients with pulmonary tuberculosis.
Methods: Randomized open label trial. Thirty patients with newly diagnosed smear-positive pulmonary tuberculosis (10 per arm) were assigned to receive isoniazid (300 mg daily) and linezolid (600 mg twice daily or 600 mg once daily) for 7 days. Sputum for quantitative culture was collected for 2 days before and then daily during 7 days of study drug administration. Bactericidal activity was estimated by measuring the decline in bacilli during the first 2 days (early bactericidal activity) and the last 5 days of study drug administration (extended early bactericidal activity).
Measurements and main results: The mean early bactericidal activity of isoniazid (0.67 log10 cfu/ml/d) was greater than that of linezolid twice and once daily (0.26 and 0.18 log10 cfu/ml/d, respectively). The extended early bactericidal activity of linezolid between Days 2 and 7 was minimal.
Conclusions: Linezolid has modest early bactericidal activity against rapidly dividing tubercle bacilli in patients with cavitary pulmonary tuberculosis during the first 2 days of administration, but little extended early bactericidal activity. Clinical trial registered with www.clinicaltrials.gov (NCT00396084).
Figures

Similar articles
-
Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis.Antimicrob Agents Chemother. 2016 Oct 21;60(11):6591-6599. doi: 10.1128/AAC.01163-16. Print 2016 Nov. Antimicrob Agents Chemother. 2016. PMID: 27550361 Free PMC article. Clinical Trial.
-
Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis.Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0168421. doi: 10.1128/AAC.01684-21. Epub 2021 Dec 6. Antimicrob Agents Chemother. 2022. PMID: 34871098 Free PMC article. Clinical Trial.
-
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.Antimicrob Agents Chemother. 2020 Mar 24;64(4):e02012-19. doi: 10.1128/AAC.02012-19. Print 2020 Mar 24. Antimicrob Agents Chemother. 2020. PMID: 31988102 Free PMC article. Clinical Trial.
-
Linezolid, the first oxazolidinone antibacterial agent.Ann N Y Acad Sci. 2011 Mar;1222:49-54. doi: 10.1111/j.1749-6632.2011.05962.x. Ann N Y Acad Sci. 2011. PMID: 21434942 Review.
-
Linezolid--a review of the first oxazolidinone.Expert Opin Pharmacother. 2001 Feb;2(2):293-302. doi: 10.1517/14656566.2.2.293. Expert Opin Pharmacother. 2001. PMID: 11336587 Review.
Cited by
-
Fluoroquinolone-resistant latent tuberculosis infection: A literature review and case series of 5 patients treated with linezolid monotherapy.J Clin Tuberc Other Mycobact Dis. 2023 May 18;32:100376. doi: 10.1016/j.jctube.2023.100376. eCollection 2023 Aug. J Clin Tuberc Other Mycobact Dis. 2023. PMID: 37252368 Free PMC article.
-
Linezolid does not improve bactericidal activity of rifampin-containing first-line regimens in animal models of TB meningitis.Int J Antimicrob Agents. 2024 Jan;63(1):107048. doi: 10.1016/j.ijantimicag.2023.107048. Epub 2023 Dec 5. Int J Antimicrob Agents. 2024. PMID: 38061419 Free PMC article.
-
Recent advances in tuberculosis: New drugs and treatment regimens.Curr Respir Med Rev. 2013 Jun 1;9(3):200-210. doi: 10.2174/1573398x113099990017. Curr Respir Med Rev. 2013. PMID: 24683386 Free PMC article.
-
Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs.Eur Respir J. 2023 Aug 31;62(2):2300165. doi: 10.1183/13993003.00165-2023. Print 2023 Aug. Eur Respir J. 2023. PMID: 37321622 Free PMC article.
-
The role of delamanid in the treatment of drug-resistant tuberculosis.Ther Clin Risk Manag. 2015 May 13;11:779-91. doi: 10.2147/TCRM.S71076. eCollection 2015. Ther Clin Risk Manag. 2015. PMID: 25999726 Free PMC article. Review.
References
-
- Shinabarger D. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin Investig Drugs 1999;8:1195–1202. - PubMed
-
- Alcala L, Ruiz-Serrano MJ, Perez-Fernandez Turegano C, Garcia De Viedma D, Diaz-Infantes M, Marin-Arriaza M, Bouza E. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 2003;47:416–417. - PMC - PubMed
-
- Molicotti P, Ortu S, Bua A, Cannas S, Sechi LA, Zanetti S. In vitro efficacy of linezolid on clinical strains of Mycobacterium tuberculosis and other mycobacteria. New Microbiol 2006;29:275–280. - PubMed
-
- Rodriguez JC, Ruiz M, Lopez M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002;20:464–467. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical